Directed Evolution of a Lysosomal Enzyme with Enhanced Activity at Neutral pH by Mammalian Cell-Surface Display

Chemistry and Biology

Volumn 15, Issue 12, 2008, Pages 1277-1286

  Chen, Kai Chuan ^a,b   Wu, Chia Hung ^a   Chang, Chuan Yuan ^a   Lu, Wei Cheng ^a   Tseng, Qingzong ^a   Prijovich, Zeljko M ^a   Schechinger, Wolfgang ^a   Liaw, Yen Chywan ^c   Leu, Yu Lin ^d   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

CHEMBIO

Indexed keywords

BETA GLUCURONIDASE; MEMBRANE PROTEIN; PRODRUG;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; ENZYMOLOGY; GENETIC VARIABILITY; GENETICS; HUMAN; LYSOSOME; METABOLISM; PH; PROTEIN ENGINEERING; UPREGULATION;

ANIMALS; GENETIC VARIATION; GLUCURONIDASE; HUMANS; HYDROGEN-ION CONCENTRATION; LYSOSOMES; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PRODRUGS; PROTEIN ENGINEERING; UP-REGULATION;

EUKARYOTA; MAMMALIA;

EID: 57649143944     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.10.008     Document Type: Article

References (53)

1. Abraham S., Guo F., Li L.S., Rader C., Liu C., Barbas III C.F., Lerner R.A., and Sinha S.C. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc. Natl. Acad. Sci. USA 104 (2007) 5584-5589
2. Altamirano M.M., Blackburn J.M., Aguayo C., and Fersht A.R. Directed evolution of new catalytic activity using the α/β-barrel scaffold. Nature 403 (2000) 617-622
3. Anderson R.G., and Orci L. A view of acidic intracellular compartments. J. Cell Biol. 106 (1988) 539-543
4. Anlezark G.M., Melton R.G., Sherwood R.F., Wilson W.R., Denny W.A., Palmer B.D., Knox R.J., Friedlos F., and Williams A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50 (1995) 609-618
5. Bagshawe K.D., and Sharma S.K. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant. Proc. 28 (1996) 3156-3158
6. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., and Sherwood R.F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58 (1988) 700-703
7. Becker S., Michalczyk A., Wilhelm S., Jaeger K.E., and Kolmar H. Ultrahigh-throughput screening to identify E. coli cells expressing functionally active enzymes on their surface. ChemBioChem 8 (2007) 943-949
8. Bosslet K., Czech J., and Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54 (1994) 2151-2159
9. Cadwell R.C., and Joyce G.F. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2 (1992) 28-33
10. Chen S.H., Shine H.D., Goodman J.C., Grossman R.G., and Woo S.L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91 (1994) 3054-3057
11. Chen B.M., Cheng T.L., Tzou S.C., and Roffler S.R. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int. J. Cancer 94 (2001) 850-858
12. Chen K.C., Cheng T.L., Leu Y.L., Prijovich Z.M., Chuang C.H., Chen B.M., and Roffler S.R. Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymes. Cancer Gene Ther. 14 (2007) 187-200
13. Cheng T.L., and Roffler S. Membrane-tethered proteins for basic research, imaging, and therapy. Med. Res. Rev. 28 (2008) 885-928
14. Cheng T.L., Chou W.C., Chen B.M., Chern J.W., and Roffler S.R. Characterization of an antineoplastic glucuronide prodrug. Biochem. Pharmacol. 58 (1999) 325-328
15. Cheng T.L., Wei S.L., Chen B.M., Chern J.W., Wu M.F., Liu P.W., and Roffler S.R. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br. J. Cancer 79 (1999) 1378-1385
16. Chou W.C., Liao K.W., Lo Y.C., Jiang S.Y., Yeh M.Y., and Roffler S.R. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol. Bioeng. 65 (1999) 160-169
17. Coco W.M., Encell L.P., Levinson W.E., Crist M.J., Loomis A.K., Licato L.L., Arensdorf J.J., Sica N., Pienkos P.T., and Monticello D.J. Growth factor engineering by degenerate homoduplex gene family recombination. Nat. Biotechnol. 20 (2002) 1246-1250
18. Cox W.G., and Singer V.L. A high-resolution, fluorescence-based method for localization of endogenous alkaline phosphatase activity. J. Histochem. Cytochem. 47 (1999) 1443-1456
19. de Graaf M., Boven E., Scheeren H.W., Haisma H.J., and Pinedo H.M. β-glucuronidase-mediated drug release. Curr. Pharm. Des. 8 (2002) 1391-1403
20. Goding J.W. Conjugation of antibodies with fluorochromes: modifications to the standard methods. J. Immunol. Methods 13 (1976) 215-226
21. Grubb J.H., Vogler C., Levy B., Galvin N., Tan Y., and Sly W.S. Chemically modified {β}-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 105 (2008) 2616-2621
22. Islam M.R., Tomatsu S., Shah G.N., Grubb J.H., Jain S., and Sly W.S. Active site residues of human β-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J. Biol. Chem. 274 (1999) 23451-23455
23. Jain S., Drendel W.B., Chen Z.W., Mathews F.S., Sly W.S., and Grubb J.H. Structure of human β-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat. Struct. Biol. 3 (1996) 375-381
24. Kaur J., and Sharma R. Directed evolution: an approach to engineer enzymes. Crit. Rev. Biotechnol. 26 (2006) 165-199
25. Kim T., Mullaney E.J., Porres J.M., Roneker K.R., Crowe S., Rice S., Ko T., Ullah A.H., Daly C.B., Welch R., et al. Shifting the pH profile of Aspergillus niger PhyA phytase to match the stomach pH enhances its effectiveness as an animal feed additive. Appl. Environ. Microbiol. 72 (2006) 4397-4403
26. Liao K.W., Chou W.C., Lo Y.C., and Roffler S.R. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol. Bioeng. 73 (2001) 313-323
27. Lipovsek D., Antipov E., Armstrong K.A., Olsen M.J., Klibanov A.M., Tidor B., and Wittrup K.D. Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chem. Biol. 14 (2007) 1176-1185
28. Lorincz M.C., Parente M.K., Roederer M., Nolan G.P., Diwu Z., Martin D.I., Herzenberg L.A., and Wolfe J.H. Single cell analysis and selection of living retrovirus vector-corrected mucopolysaccharidosis VII cells using a fluorescence-activated cell sorting-based assay for mammalian β-glucuronidase enzymatic activity. J. Biol. Chem. 274 (1999) 657-665
29. Makde R.D., Dikshit K., and Kumar V. Protein engineering of class-A non-specific acid phosphatase (PhoN) of Salmonella typhimurium: modulation of the pH-activity profile. Biomol. Eng. 23 (2006) 247-251
30. Marais R., Spooner R.A., Stribbling S.M., Light Y., Martin J., and Springer C.J. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 15 (1997) 1373-1377
31. Marshall C.J., Franks L.M., and Carbonell A.W. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J. Natl. Cancer Inst. 58 (1977) 1743-1751
32. Matsumura I., and Ellington A.D. In vitro evolution of β-glucuronidase into a β-galactosidase proceeds through non-specific intermediates. J. Mol. Biol. 305 (2001) 331-339
33. Mayer A., Sharma S.K., Tolner B., Minton N.P., Purdy D., Amlot P., Tharakan G., Begent R.H., and Chester K.A. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90 (2004) 2402-2410
34. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46 (1986) 5276-5281
35. Mullen C.A., Kilstrup M., and Blaese R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89 (1992) 33-37
36. Napier M.P., Sharma S.K., Springer C.J., Bagshawe K.D., Green A.J., Martin J., Stribbling S.M., Cushen N., O'Malley D., and Begent R.H. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 6 (2000) 765-772
37. Olsen M.J., Stephens D., Griffiths D., Daugherty P., Georgiou G., and Iverson B.L. Function-based isolation of novel enzymes from a large library. Nat. Biotechnol. 18 (2000) 1071-1074
38. Paragas V.B., Kramer J.A., Fox C., Haugland R.P., and Singer V.L. The ELF-97 phosphatase substrate provides a sensitive, photostable method for labelling cytological targets. J. Microsc. 206 (2002) 106-119
39. Rivory L.P. Irinotecan (CPT-11): a brief overview. Clin. Exp. Pharmacol. Physiol. 23 (1996) 1000-1004
40. Roffler S.R., Wang S.M., Chern J.W., Yeh M.Y., and Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. 42 (1991) 2062-2065
41. Russell A.J., and Fersht A.R. Rational modification of enzyme catalysis by engineering surface charge. Nature 328 (1987) 496-500
42. Senter P.D., Saulnier M.G., Schreiber G.J., Hirschberg D.L., Brown J.P., Hellstrom I., and Hellstrom K.E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85 (1988) 4842-4846
43. Sharma S.K., Bagshawe K.D., Melton R.G., and Sherwood R.F. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. 21 (1992) 109-120
44. Sharma S.K., Bagshawe K.D., Melton R.G., and Begent R.H. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant. Proc. 28 (1996) 3154-3155
45. Shipley J.M., Grubb J.H., and Sly W.S. The role of glycosylation and phosphorylation in the expression of active human β-glucuronidase. J. Biol. Chem. 268 (1993) 12193-12198
46. Smith G.K., Banks S., Blumenkopf T.A., Cory M., Humphreys J., Laethem R.M., Miller J., Moxham C.P., Mullin R., and Ray P.H. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem. 272 (1997) 15804-15816
47. Spencer D.I., Robson L., Purdy D., Whitelegg N.R., Michael N.P., Bhatia J., Sharma S.K., Rees A.R., Minton N.P., Begent R.H., et al. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2 (2002) 271-279
48. Stemmer W.P. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370 (1994) 389-391
49. Svensson H.P., Vrudhula V.M., Emswiler J.E., MacMaster J.F., Cosand W.L., Senter P.D., and Wallace P.M. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res. 55 (1995) 2357-2365
50. Telford W., Cox W., and Singer V. Detection of endogenous and antibody-conjugated alkaline phosphatase with ELF-97 phosphate in multicolor flow cytometry applications. Cytometry 43 (2001) 117-125
51. Varadarajan N., Gam J., Olsen M.J., Georgiou G., and Iverson B.L. Engineering of protease variants exhibiting high catalytic activity and exquisite substrate selectivity. Proc. Natl. Acad. Sci. USA 102 (2005) 6855-6860
52. Wang S.M. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52 (1992) 4484-4491
53. Wu C.H., Balasubramanian W.R., Ko Y.P., Hsu G., Chang S.E., Prijovich Z.M., Chen K.C., and Roffler S.R. A simple method for the production of recombinant proteins from mammalian cells. Biotechnol. Appl. Biochem. 40 (2004) 167-172